A Single-centre, Double-blind, Placebo-controlled, Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3

Trial Profile

A Single-centre, Double-blind, Placebo-controlled, Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2016

At a glance

  • Drugs MGB BP 3 (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions; First in man
  • Sponsors MGB Biopharma
  • Most Recent Events

    • 14 Jun 2016 Data will be presented at the ASM Microbe 2016 meeting, according to a MGB Biopharma media release.
    • 14 Jun 2016 Results published in a MGB Biopharma media release.
    • 09 May 2016 According to a MGB Biopharma media release, data from this study was presented during a pre-Investigational New Drug (pre-IND) meeting with the Food and Drug Administration (FDA) to discuss the regulatory strategy for the development programme of MGB-BP-3 in the US.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top